Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats

Molecular Pharmacology

Volumn 61, Issue 2, 2002, Pages 360-368

  Glavan, Gordana ^a   Sket, Dušan ^a   Živin, Marko ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 9,10 DIDEHYDRO N METHYL (2 PROPYNYL) 6 METHYL 8 AMINOMETHYLERGOLINE BIMALEINATE; ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; LEK 8829; MESSENGER RNA; NEUROLEPTIC AGENT; NEUROTENSIN; OXIDOPAMINE; PREPROTACHYKININ; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; FEMALE; IN SITU HYBRIDIZATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FEMALE; GENE EXPRESSION; LYSERGIC ACID; NEUROTENSIN; OXIDOPAMINE; QUINPIROLE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE;

EID: 0036151378     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.2.360     Document Type: Article

References (29)

1. Clozapine: Dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs
2. A complex program of striatal gene expression induced by dopaminergic stimulation
3. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopaminelesioned rate
4. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: The effects of chronic exposure on behavior and receptor binding in rats and their clinical implications
5. The neuroleptics: A historical survey
6. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
7. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion
8. Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway
9. Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 dopamine receptors
10. Dopamine D1- and D2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats
11. Does neurotensin mediate the effects of antipsychotic drugs?
12. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841
13. A new ergoline derivative, LEK-8829, as a potential new antipsychotic drug
14. The cerebral cortex: A case for a common site of action of antipsychotics
15. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values
16. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists
17. Neurotensin: Perchance an endogenous neuroleptic?
18. Pathophysiology of the basal ganglia in Parkinson's disease
19. Pharmacological and molecular targets in the search for novel antipsychotics
20. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons
21. Gene expression in striatal grafts-I. Cellular localization of neurotransmitter mRNAs
22. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression
23. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway
24. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: Interaction with bromocriptine
25. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system
26. Serotonin regulation of tachykinin biosynthesis in the rat neostriatum
27. The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions
28. Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine